In this post hoc subgroup analysis, first-line cemiplimab significantly improved PFS and numerically improved OS and ORR vs platinum-based chemotherapy in patients with locally advanced NSCLC and PD-L1 ≥50% who were ineligible for definitive concurrent chemoradiotherapy or had recurrence after concurrent chemoradiotherapy.
In this updated analysis, datopotamab deruxtecan was associated with durable antitumor activity and a manageable safety profile in patients with heavily pretreated advanced NSCLC.
First-line treatment with nivolumab plus ipilimumab plus chemotherapy was associated with improved systemic and intracranial outcomes in patients with advanced NSCLC, both with and without brain metastases at baseline.
In this phase II study, atezolizumab plus carboplatin/pemetrexed was well tolerated and showed concordant systemic and intracranial efficacy in patients with advanced NSCLC and untreated brain metastases.
In this analysis of a dose-expansion cohort from an ongoing phase I/II trial, mobocertinib was associated with clinical activity and manageable safety in patients with EGFR ex20ins–positive advanced NSCLC with disease progression after responding to or achieving stable disease on prior EGFR TKI therapy.
EGFR/HER2 inhibitor DZD9008 was well tolerated with promising antitumor activity in patients with EGFR ex20ins mutation–positive advanced NSCLC with or without brain metastasis.
Phase I results suggest promising clinical activity with amivantamab in unresectable or metastatic NSCLC driven by a MET exon 14 skipping mutation.
Expanded analysis of cohort of patients with TRK fusion–positive lung cancer who received larotrectinib in a phase I or II basket trial suggests rapid, durable activity with larotrectinib, including in patients with CNS disease.
Durvalumab plus chemotherapy significantly improved PFS vs chemotherapy alone in patients with previously untreated metastatic NSCLC.
In this phase III trial, the combination of lurbinectedin plus doxorubicin was not associated with a survival benefit over standard chemotherapy in patients with relapsed SCLC.
DFS benefit with adjuvant atezolizumab vs best supportive care was seen across most disease stages and prior treatments.
Early data suggest that mesothelin-targeted CAR T-cell therapy with or without pembrolizumab is associated with a tolerable safety profile and clinical activity in patients with malignant pleural cancers.